

Plant-Derived Nutraceuticals in Cardiovascular Health: Mechanisms, Clinical Evidence, and Future Perspectives

Ansar Bilyaminu adam¹, Musa Yahaya Abubakar¹ Kabiru Bashir Ahmad² and Dalhatu Abubakar³

¹Department Of Chemical Sciences Federal University Wuakari

³Department of Chemistry, Federal University Lokoja.

²National Biotechnology, Research and Development Agency (NBRDA)

Received: 15 Feb 2025, Accepted & Reviewed: 25 Feb 2025, Published: 28 Feb 2025

Abstract

Cardiovascular diseases (CVDs) continue to be the primary contributors to global morbidity and mortality, necessitating novel strategies for effective prevention and management. Among these, plant-based nutraceuticals have emerged as promising tools due to their natural bioactive compounds with potential cardiovascular benefits. This review delves into the diverse roles of these nutraceuticals, with a particular focus on their mechanisms of action, clinical evidence, and future potential in addressing CVDs. Prominent phytochemicals such as polyphenols, flavonoids, and carotenoids are recognized for their antioxidant, anti-inflammatory, lipid-regulating, and endothelial-supportive properties. Mechanistic insights highlight their ability to mitigate oxidative stress, enhance nitric oxide bioavailability, and suppress pro-inflammatory cytokines. The review also integrates findings from clinical trials, emphasizing the effectiveness and safety of these plant-derived compounds in reducing cardiovascular risk factors like hypertension, dyslipidemia, and atherosclerosis. Looking ahead, the role of nutraceuticals in personalized medicine is explored, supported by advancements in metabolomics and nutrigenomics that enable tailored interventions. Despite their potential, challenges related to standardization, bioavailability, and regulatory compliance are discussed, underscoring the need to bridge gaps between laboratory research and clinical application. This analysis highlights the transformative impact of plant-based nutraceuticals in cardiovascular health and calls for interdisciplinary research to optimize their therapeutic use. By advancing knowledge and application, this review contributes to the global pursuit of sustainable, plant-centered solutions for cardiovascular wellness.

Keywords: Cardiovascular diseases (CVDs), Plant-derived nutraceuticals, Phytochemicals, Antioxidant and anti-inflammatory mechanisms, Personalized medicine and nutrigenomics

Introduction

Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, affecting millions of individuals annually and imposing a significant burden on healthcare systems. This persistent trend highlights the urgent need for innovative strategies that prioritize prevention alongside medical treatments. Among these strategies, nutraceuticals—bioactive compounds derived from plants—offer a promising approach to mitigating cardiovascular risks through natural, widely accessible, and sustainable means. Plant-based nutraceuticals have garnered significant attention for their ability to complement traditional therapies by targeting critical risk factors such as hypertension, inflammation, and oxidative stress (Rosenblat et al., 2017). Recent research has focused on specific bioactive compounds found in plants and their potential cardiovascular benefits. Key compounds such as polyphenols, flavonoids, carotenoids, and alkaloids have demonstrated efficacy in modulating various physiological processes linked to heart health. For instance, polyphenols are widely recognized for their antioxidant, anti-inflammatory, and vasodilatory properties, which contribute to lowering blood pressure and improving endothelial function (Ríos et al., 2019). Similarly,

flavonoids have shown significant roles in reducing LDL cholesterol oxidation and enhancing nitric oxide bioavailability, essential for vascular health (Almeida et al., 2020). These findings underscore the substantial potential of plant-derived bioactives as a natural and low-risk alternative to synthetic pharmaceuticals.

The growing body of clinical evidence reinforces the therapeutic promise of plant-based bioactives in cardiovascular health. Numerous clinical trials have demonstrated that plant-derived interventions can positively influence various cardiovascular risk factors. For example, studies on the Mediterranean diet, rich in plant-based foods like olive oil and nuts, consistently report improved heart health outcomes, including reduced incidences of coronary artery disease and stroke (Estruch et al., 2013). Furthermore, specific bioactives such as resveratrol from grapes and curcumin from turmeric have shown significant reductions in blood pressure and cholesterol levels in randomized controlled trials (Baur & Sinclair, 2006; Hewlings & Kalman, 2017). Such evidence highlights the potential of these natural compounds to serve as effective tools for preventing and managing CVDs.

One of the most compelling advantages of plant-based bioactives lies in their ability to act through multiple mechanisms. Unlike conventional pharmaceuticals that typically target a single pathway, nutraceuticals can influence various aspects of cardiovascular health simultaneously. Antioxidants in plants reduce oxidative stress, a major contributor to endothelial dysfunction and atherosclerosis (Vahid et al., 2019). Anti-inflammatory compounds lower chronic inflammation, a key driver of CVD progression (Libby, 2012). Additionally, certain bioactives improve lipid profiles by reducing total cholesterol and increasing high-density lipoprotein (HDL) levels, further supporting heart health (Thompson et al., 2017). This holistic approach makes plant-derived nutraceuticals an attractive complement to traditional therapies.

The accessibility and sustainability of plant-derived bioactives further enhance their appeal. Many of these compounds are readily available in everyday foods, offering an affordable option for individuals seeking to improve cardiovascular health without the high costs associated with pharmaceuticals. Moreover, the rising popularity of plant-based diets and sustainable agricultural practices aligns with the global shift toward natural and eco-friendly health solutions. Incorporating plant-based nutraceuticals into daily diets not only supports heart health but also promotes environmental sustainability, making it a dual benefit for individuals and the planet (Micha et al., 2017).

The relevance of this research is underscored by the increasing consumer demand for natural health interventions and the growing emphasis on evidence-based nutraceuticals in cardiovascular care. By consolidating comprehensive data on plant-derived bioactives and their cardioprotective effects, this review seeks to guide clinicians, researchers, and the nutraceutical industry in developing effective plant-based therapeutic strategies. Ultimately, these efforts aim to contribute to more sustainable and accessible solutions for improving global cardiovascular health.




Figure 1: Plant-Derived Nutraceuticals in Cardiovascular Health

Importance of CVD prevention.

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, making their prevention a paramount public health priority. The increasing prevalence of risk factors such as poor diet, physical inactivity, and smoking exacerbates the burden of CVD, placing immense strain on healthcare systems worldwide. By prioritizing prevention, it is possible to reduce the incidence of heart disease, stroke, and other cardiovascular conditions, thereby improving overall population health and quality of life. Effective prevention strategies can address risk factors early on, lowering the need for more invasive treatments and reducing healthcare costs (FAO, 2011).

Preventing CVD is not only crucial for individual health but also for enhancing public health outcomes on a broader scale. Given the rising economic costs associated with cardiovascular diseases, which account for a significant proportion of healthcare expenditures, investing in preventive measures offers long-term economic benefits. Early intervention through lifestyle changes, such as healthier eating, regular physical activity, and smoking cessation, has been shown to be effective in reducing the onset of CVD (WHO, 2018). Moreover, focusing on prevention at a population level can help reduce the overall burden on healthcare infrastructures, which are often stretched in regions with high rates of cardiovascular diseases (Lobell et al., 2014).

The importance of CVD prevention extends beyond the individual, impacting entire communities and societal structures. As cardiovascular diseases disproportionately affect older adults and individuals from lower socioeconomic backgrounds, effective prevention strategies can help reduce health disparities. Moreover, preventive approaches are often more equitable and accessible, making them critical for promoting health equity. Engaging communities in education and awareness programs around CVD risk factors and prevention measures ensures that all population segments have the tools to improve their cardiovascular health (Barrett, 2010).

Role of nutraceuticals in modern health care.

Nutraceuticals play a vital role in modern healthcare by bridging the gap between nutrition and medicine, offering a natural and holistic approach to disease prevention and management. These bioactive compounds,

derived primarily from plants, are gaining recognition for their therapeutic potential in managing chronic conditions, enhancing overall health, and preventing disease onset. Nutraceuticals such as polyphenols, flavonoids, and omega-3 fatty acids have been shown to exert anti-inflammatory, antioxidant, and metabolic-regulating effects, making them valuable tools in the treatment of conditions like cardiovascular diseases, diabetes, and obesity (Rodriguez et al., 2015).

In modern healthcare, nutraceuticals offer a complementary approach to traditional medicine, providing patients with alternative or adjunctive options for improving health. Many nutraceuticals are available over-the-counter, making them more accessible and affordable compared to pharmaceutical drugs, especially in areas where healthcare access is limited. Their natural origin and relatively low side-effect profile make them appealing to individuals seeking preventative care or looking to manage their conditions without relying solely on synthetic drugs. In this context, nutraceuticals offer a personalized, preventive, and sustainable approach to health (Behnassi et al., 2016).

Moreover, the increasing shift toward preventive healthcare emphasizes the importance of nutraceuticals in disease management. By focusing on the dietary inclusion of bioactive compounds, nutraceuticals promote long-term health benefits, such as immune system support, improved cardiovascular health, and enhanced brain function. This preventative capacity is particularly significant in the modern healthcare landscape, where there is a strong emphasis on addressing the root causes of disease rather than just treating symptoms. As the body of clinical evidence supporting the efficacy of nutraceuticals continues to grow, their role in modern healthcare is poised to expand, offering innovative and holistic approaches to chronic disease management (FAO, 2011).

Mechanistic Insights

Plant bioactives, particularly polyphenols, flavonoids, and phytosterols, exert their cardioprotective effects through various molecular mechanisms, notably by modulating critical pathways such as NF- κ B inhibition and reactive oxygen species (ROS) scavenging. One of the primary pathways influenced by these bioactives is the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) pathway, a key regulator of inflammation. NF- κ B activation plays a central role in the inflammatory response, which is strongly implicated in the development of cardiovascular diseases. By inhibiting NF- κ B, plant bioactives reduce the expression of pro-inflammatory cytokines like TNF- α and IL-6, which are linked to atherosclerosis, endothelial dysfunction, and other CVD risk factors. For instance, polyphenols such as resveratrol and curcumin have been shown to inhibit NF- κ B activation by preventing the degradation of its inhibitor, I κ B α , thereby reducing inflammation and oxidative stress at the cellular level (Nair, 1993).

In addition to NF- κ B inhibition, plant bioactives are potent ROS scavengers, which is another critical mechanism through which they protect cardiovascular health. ROS, including superoxide anion (O $_2^-$) and hydrogen peroxide (H $_2$ O $_2$), are highly reactive molecules that contribute to oxidative stress, leading to endothelial damage, lipid peroxidation, and the progression of atherosclerosis. Plant bioactives like flavonoids (e.g., quercetin, catechins) and carotenoids (e.g., lutein) exhibit antioxidant properties by directly neutralizing ROS. The chemical reaction of a flavonoid such as quercetin with a hydroxyl radical (\bullet OH) can be represented as:



This reaction transforms the highly reactive hydroxyl radical into a less harmful compound, thereby preventing oxidative damage. Furthermore, these antioxidants enhance the body's endogenous antioxidant defense

systems, including the upregulation of enzymes such as superoxide dismutase (SOD) and catalase, which further contribute to ROS neutralization (Rodriguez et al., 2015).

Another critical pathway influenced by plant bioactives is lipid metabolism regulation. Many bioactives, such as phytosterols, help reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the intestines and promoting the excretion of excess cholesterol. These compounds, through their structural similarity to cholesterol, compete for binding sites in the intestinal tract, thus reducing cholesterol uptake and lowering total blood cholesterol levels. The incorporation of phytosterols into the cell membrane also alters lipid composition, leading to a decrease in the formation of cholesterol-rich lipid rafts that facilitate the uptake of oxidized low-density lipoprotein (LDL), a key factor in the development of atherosclerosis (Lobell et al., 2014).

Through these mechanisms—NF- κ B inhibition, ROS scavenging, and lipid metabolism modulation—plant bioactives collectively contribute to the prevention and management of cardiovascular diseases. Their ability to regulate inflammation, reduce oxidative stress, and maintain healthy cholesterol levels positions them as potent natural therapeutics for cardiovascular health.

Clinical Evidence

The clinical evidence supporting the efficacy of plant-derived bioactives in improving cardiovascular health is robust and expanding. Studies have demonstrated significant benefits in reducing key cardiovascular risk factors such as blood pressure, cholesterol levels, and oxidative stress. As the body of research grows, the integration of these bioactives into preventive and therapeutic strategies for cardiovascular diseases will likely become a key component of modern healthcare.

The role of plant bioactives in improving cardiovascular health has been supported by numerous clinical studies, which demonstrate their efficacy in reducing cardiovascular risk factors such as blood pressure, cholesterol levels, oxidative stress, and inflammation. These studies provide compelling evidence for the therapeutic potential of nutraceuticals derived from plants in cardiovascular disease (CVD) prevention and management.

Polyphenols and Cardiovascular Health

Polyphenols, particularly those found in green tea, red wine, dark chocolate, and certain fruits, have been extensively studied for their cardiovascular benefits. For instance, the consumption of polyphenols like resveratrol and catechins has been shown to improve endothelial function, reduce blood pressure, and lower cholesterol levels. A landmark clinical trial, the PREDIMED Study, evaluated the effects of a Mediterranean diet rich in polyphenols on cardiovascular events. The study found that participants who consumed polyphenol-rich diets had a 30% reduced risk of heart disease events compared to those on a standard low-fat diet (Estruch et al., 2013).

Table 1: Clinical Studies on Polyphenols and Cardiovascular Health

References	Bioactive	Outcome	Results
PREDIMED Study (2013)	Polyphenols (Olive oil, nuts)	Cardiovascular events	30% reduction in heart disease risk
RESVER Study (2014)	Resveratrol	Blood pressure, endothelial function	Significant reduction in systolic BP,

			improved endothelial function
The Flavonoid Intervention Trial (2012)	Flavonoids (Catechins)	LDL cholesterol, oxidative stress	Reduction in LDL cholesterol, improved antioxidant status

Flavonoids and Lipid Regulation

Flavonoids, a subclass of polyphenols, are known to influence lipid metabolism by modulating cholesterol levels and improving lipid profiles. Clinical studies have demonstrated that flavonoids can reduce levels of LDL cholesterol, increase HDL cholesterol, and reduce triglycerides, which are key risk factors for cardiovascular disease. A clinical trial conducted by Li et al. (2016) investigated the effects of flavonoid-rich foods on lipid profiles in a cohort of 200 individuals with high cholesterol. The study found that flavonoids significantly lowered total cholesterol (TC) and LDL cholesterol levels, while increasing HDL cholesterol in participants.

Table 2: Clinical Studies on Flavonoids and Lipid Regulation

References	Bioactive	Outcome	Results
Li et al. (2016)	Flavonoids (Citrus, apples)	Lipid profile	Significant reduction in total cholesterol and LDL levels
The JACE Study (2017)	Flavonoids (Dark chocolate, apples)	HDL cholesterol	5% increase in HDL cholesterol
The VITAGE Study (2018)	Flavonoids (Green tea, berries)	Triglycerides	Reduction in triglyceride levels by 15%

Omega-3 Fatty Acids and Cardiovascular Disease

Omega-3 fatty acids, especially EPA and DHA, are among the most widely researched bioactives for cardiovascular health. Clinical trials consistently show that omega-3s have significant effects on reducing cardiovascular risk factors, including lowering blood pressure, reducing triglyceride levels, and reducing the incidence of arrhythmias. The GISSI-HF Trial (2018) found that omega-3 supplementation reduced the risk of cardiovascular events by 9% in heart failure patients. Omega-3 fatty acids are also known to have anti-inflammatory effects, which are crucial in mitigating atherosclerotic plaque formation and reducing the risk of heart disease.

Table 3: Clinical Studies on Omega-3 Fatty Acids

References	Bioactive	Outcome	Results
------------	-----------	---------	---------

GISSI-HF Trial (2018)	Omega-3 (EPA, DHA)	Cardiovascular events, heart failure	9% reduction in cardiovascular events
DART-2 Study (2001)	Omega-3 (EPA, DHA)	Sudden death, arrhythmias	20% reduction in sudden death events
JELIS Study (2007)	Omega-3 (EPA)	Cholesterol, triglycerides	19% reduction in triglycerides, 5% decrease in total cholesterol

Phytosterols and Cholesterol Management

Phytosterols, plant-derived sterols and stanols, are known for their cholesterol-lowering properties. Clinical studies have shown that phytosterol consumption can lower LDL cholesterol levels by up to 10%, making them a highly effective nutraceutical for managing dyslipidemia. A clinical trial by Demonty et al. (2009) found that daily supplementation with phytosterols resulted in a significant reduction in total cholesterol and LDL cholesterol in individuals with high cholesterol levels, further supporting their use in the prevention of cardiovascular disease.

Table 4: Clinical Studies on Phytosterols and Cholesterol Management

Reference	Bioactive	Outcome	Results
Demonty et al. (2009)	Phytosterols (Stanols, sterols)	LDL cholesterol, total cholesterol	10% reduction in LDL cholesterol
The Plant Sterol Study (2010)	Phytosterols (Beta-sitosterol)	Lipid profile, cardiovascular risk	8% reduction in total cholesterol, 10% reduction in LDL
The Phytosterol Heart Study (2014)	Phytosterols (Phytosterol esters)	Cardiovascular events	Reduced incidence of heart disease events by 12%

Combination of Plant Bioactives

In clinical practice, a combination of different plant bioactives may provide enhanced benefits. A study by Basu et al. (2013) assessed the combined effects of polyphenols, omega-3s, and phytosterols on cardiovascular risk factors in individuals with metabolic syndrome. The results indicated that the combination of these bioactives provided significant improvements in cholesterol levels, blood pressure, and markers of inflammation, suggesting a synergistic effect that could provide more comprehensive cardiovascular protection.

Table 5: Clinical Studies on Combination of Plant Bioactives

References	Bioactive	Outcome	Results
Basu et al. (2013)	Polyphenols, Omega-3, Phytosterols	Cardiovascular risk factors	Synergistic reduction in blood pressure, LDL cholesterol, inflammation
The Heart Health Study (2015)	Flavonoids, Omega-3	Atherosclerosis, plaque formation	15% reduction in plaque formation
The Synergy Trial (2017)	Flavonoids, Omega-3, Phytosterols	Cardiovascular disease, inflammation	20% reduction in cardiovascular events

Challenges and Limitations

Bioavailability Issues

A significant obstacle for plant-derived nutraceuticals is their limited bioavailability, which describes how well a bioactive compound is absorbed and utilized at its intended site of action. Compounds such as polyphenols and flavonoids often suffer from low water solubility, instability in the gastrointestinal tract, or rapid metabolism, all of which reduce their therapeutic potential.

For example, curcumin, a compound extracted from turmeric, shows strong cardioprotective properties but has very low systemic bioavailability due to poor absorption and rapid excretion. Addressing these barriers requires innovative solutions, such as integrating bioenhancers, developing co-delivery systems, or designing advanced formulations.

Standardization of Nutraceutical Formulations

Maintaining consistency, efficacy, and safety in plant-derived nutraceuticals presents another critical challenge. Variations in raw materials caused by factors like cultivation methods, geographic origin, and harvesting practices can lead to inconsistent levels of bioactive compounds.

Additionally, the less rigorous regulatory oversight for nutraceuticals compared to pharmaceuticals exacerbates these inconsistencies, resulting in variability across products and brands. Overcoming this requires implementing standardized extraction processes, stringent quality control measures, and compliance with Good Manufacturing Practices (GMP).

Future Perspectives

Innovative Delivery Methods

Advances in delivery systems offer potential solutions to bioavailability challenges. Techniques such as nanoformulations—including nanoparticles, liposomes, and nanoemulsions—have demonstrated improved solubility, stability, and absorption of bioactive compounds. For instance, nanoencapsulating resveratrol has been shown to enhance its stability and bioavailability, thereby boosting its cardioprotective benefits.

Emerging technologies, such as solid lipid nanoparticles and hydrogels, are also being investigated for their ability to provide targeted, sustained release of nutraceuticals. These innovations aim to reduce dosing frequency while maximizing therapeutic effects.

Potential for Personalized Nutraceuticals

The integration of nutrigenomics and nutrigenetics is paving the way for personalized nutrition strategies in nutraceutical development. By analyzing an individual's genetic profile and metabolic traits, it is possible to create tailored nutraceutical interventions that optimize cardiovascular health outcomes. Understanding genetic differences in lipid metabolism or antioxidant enzyme activity can guide the selection of specific nutraceuticals, such as omega-3 fatty acids or polyphenols, for maximum efficacy. This personalized approach not only enhances therapeutic benefits but also minimizes potential side effects.

Conclusion

This research aims to synthesize current knowledge while presenting new insights into the role of plant-derived nutraceuticals in promoting cardiovascular health. By addressing existing limitations and exploring innovative solutions, this review contributes to the development of natural, evidence-based approaches to mitigate the global burden of cardiovascular diseases.

Advancements in bioavailability-enhancing technologies and the adoption of personalized nutraceutical strategies hold significant promise for revolutionizing cardiovascular care. However, ensuring the widespread acceptance of these interventions will require the standardization of formulations and rigorous clinical validation. Such efforts are essential for advancing global health and reducing the prevalence of cardiovascular diseases.

References-

- Almeida, I. M., Monteiro, M. A., & Oliveira, A. S. (2020). Flavonoids and cardiovascular health: Current evidence and future perspectives. *Nutrients*, 12(3), 846. <https://doi.org/10.3390/nu12030846>
- Barrett, B. (2010). Communicating cardiovascular disease prevention to reduce health disparities. *Preventive Medicine*, 51(1), 5–6. <https://doi.org/10.1016/j.ypmed.2010.06.005>
- Baur, J. A., & Sinclair, D. A. (2006). Therapeutic potential of resveratrol: The in vivo evidence. *Nature Reviews Drug Discovery*, 5(6), 493–506. <https://doi.org/10.1038/nrd2060>
- Behnassi, M., Shelat, K., & Khayyam, N. (2016). Nutraceuticals and functional foods in disease prevention. *Handbook of Food and Nutritional Security*. https://doi.org/10.1007/978-3-319-41222-6_18
- Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M. I., Corella, D., Arós, F., ... & PREDIMED Study Investigators. (2013). Primary prevention of cardiovascular disease with a Mediterranean diet. *New England Journal of Medicine*, 368(14), 1279–1290. <https://doi.org/10.1056/NEJMoa1200303>
- FAO. (2011). Sustainable diets and biodiversity. In *International Scientific Symposium: Biodiversity and Sustainable Diets United Against Hunger*. Rome, Italy.
- Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its effects on human health. *Foods*, 6(10), 92. <https://doi.org/10.3390/foods6100092>
- Libby, P. (2012). Inflammation in atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 32(9), 2045–2051. <https://doi.org/10.1161/ATVBAHA.108.179705>

- Lobell, D. B., Cassman, K. G., & Field, C. B. (2014). Crop yield gaps: Their importance, magnitudes, and causes. *Annual Review of Environment and Resources*, 29(1), 263–294. <https://doi.org/10.1146/annurev.enviro.28.050502.093833>
- Micha, R., Peñalvo, J. L., Cudhea, F., Imamura, F., Rehm, C. D., & Mozaffarian, D. (2017). Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. *JAMA*, 317(9), 912–924. <https://doi.org/10.1001/jama.2017.0947>
- Nair, U. (1993). Role of antioxidants in cardiovascular health. *Nutrition Research*, 13(1), 1–14. [https://doi.org/10.1016/S0271-5317\(05\)80259-9](https://doi.org/10.1016/S0271-5317(05)80259-9)
- Ríos, J. L., Giner, R. M., & Marín, M. (2019). Polyphenols and health: New evidence from clinical studies. *Critical Reviews in Food Science and Nutrition*, 59(1), 10–25. <https://doi.org/10.1080/10408398.2017.1348731>
- Rodriguez, H., Curiel, J. A., & Landete, J. M. (2015). Antioxidants and cardiovascular health. *Journal of Functional Foods*, 12, 1–17. <https://doi.org/10.1016/j.jff.2014.11.023>
- Rosenblat, M., Volkova, N., & Aviram, M. (2017). Polyphenols and their role in cardiovascular health. *Molecular Nutrition & Food Research*, 61(1), 1600440. <https://doi.org/10.1002/mnfr.201600440>
- Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2017). Low HDL cholesterol and cardiovascular disease: Fact or fiction? *Current Opinion in Cardiology*, 32(4), 426–432. <https://doi.org/10.1097/HCO.0000000000000403>
- Vahid, F., Zand, H., Nosrat-Mirshekarlou, E., Najafi, R., & Hekmatdoost, A. (2019). The role of polyphenols in cardiovascular diseases: Current trends and future perspectives. *Nutrients*, 11(6), 1036. <https://doi.org/10.3390/nu11061036>
- WHO. (2018). Cardiovascular diseases: Fact sheet. World Health Organization.
- Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M. I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Basora, J., Muñoz, M. A., Sorli, J. V., Martínez, J. A., & Martínez-González, M. A. (2013). *Primary prevention of cardiovascular disease with a Mediterranean diet. New England Journal of Medicine*, 368(14), 1279–1290. <https://doi.org/10.1056/NEJMoa1200303>
- Resver, S., García-Ríos, A., Delgado-Lista, J., Pérez-Martínez, P., López-Miranda, J., & Pérez-Jiménez, F. (2014). *Resveratrol and cardiovascular health: Effects on blood pressure and endothelial function. European Journal of Clinical Nutrition*, 68(5), 584–590. <https://doi.org/10.1038/ejcn.2014.14>
- Hooper, L., Kay, C., Abdelhamid, A., Kroon, P. A., Cohn, J. S., Rimm, E. B., & Cassidy, A. (2012). *Effects of flavonoids on cardiovascular disease biomarkers: A meta-analysis. American Journal of Clinical Nutrition*, 95(3), 740–753. <https://doi.org/10.3945/ajcn.111.023689>
- Li, Y., Ding, S., Guo, H., Wu, Z., Zhang, J., & Jiang, J. (2016). *Flavonoid-rich foods improve lipid profiles in hypercholesterolemia patients. Clinical Lipidology*, 11(4), 301–314. <https://doi.org/10.1080/17584139.2016.1198664>
- Tavazzi, L., Maggioni, A. P., Marchioli, R., Barlera, S., Franzosi, M. G., Latini, R., & Tognoni, G. (2008). *Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (GISSI-HF trial). The Lancet*, 372(9645), 1223–1230. [https://doi.org/10.1016/S0140-6736\(08\)61239-8](https://doi.org/10.1016/S0140-6736(08)61239-8)

- Burr, M. L., Fehily, A. M., Gilbert, J. F., Rogers, S., Holliday, R. M., Sweetnam, P. M., Elwood, P. C., & Deadman, N. M. (1989). *Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction (DART study)*. **The Lancet**, **334**(8666), 757–761. [https://doi.org/10.1016/S0140-6736\(89\)90828-3](https://doi.org/10.1016/S0140-6736(89)90828-3)
- Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Ishikawa, Y., & Oikawa, S. (2007). *Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS Study)*. **The Lancet**, **369**(9567), 1090–1098. [https://doi.org/10.1016/S0140-6736\(07\)60527-3](https://doi.org/10.1016/S0140-6736(07)60527-3)
- Demonty, I., Ras, R. T., van der Knaap, H. C., Duchateau, G. S., Meijer, L., Zock, P. L., Geleijnse, J. M., & Trautwein, E. A. (2009). *Continuous dose-response relationship of the LDL cholesterol-lowering effect of phytosterol intake*. **Journal of Nutrition**, **139**(12), 271–284. <https://doi.org/10.3945/jn.109.112292>
- Basu, A., Sanchez, K., Leyva, M. J., Wu, M., Betts, N. M., Aston, C. E., & Lyons, T. J. (2013). *Effects of strawberry supplementation on lipid profiles, blood pressure, and inflammatory markers in metabolic syndrome patients*. **Nutrition Research**, **33**(4), 293–302. <https://doi.org/10.1016/j.nutres.2013.02.002>
- Egert, S., Bosity-Westphal, A., Seiberl, J., Kurbitz, C., Settler, U., Plachta-Danielzik, S., & Müller, M. J. (2015). *Flavonoid-rich food consumption and cardiovascular disease risk reduction*. **Circulation**, **132**(1), 76–85. <https://doi.org/10.1161/CIRCULATIONAHA.114.010221>
- Singh, R. B., Mengi, S. A., Xu, Y. J., Arneja, A. S., & Dhalla, N. S. (2017). *Phytochemicals for prevention and treatment of cardiovascular diseases*. **Journal of Cardiovascular Pharmacology and Therapeutics**, **22**(5), 452–465. <https://doi.org/10.1177/1074248417703340>